Antiepileptic medications in multiple sclerosis: Adverse effects in a three-year follow-up study

Neurological Sciences

Volumn 25, Issue 6, 2005, Pages 307-310

  Solaro, C ^a   Brichetto, G ^b   Battaglia, M A ^c   Messmer Uccelli, M ^d   Mancardi, G L ^b  

^a PA Micone Hospital   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Italian Multiple Sclerosis Society   (Italy)

Author keywords

Adverse effects; Antiepileptic medications; Carbamazepine; Gabapentin; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ADULT; ARTICLE; ASTHENIA; CLINICAL FEATURE; COMPUTER SYSTEM; DATA BASE; DISEASE EXACERBATION; DIZZINESS; EXPANDED DISABILITY STATUS SCALE; GAIT DISORDER; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; OBSERVATION; PYRAMIDAL SIGN; RELAPSE; SKIN ALLERGY; SYMPTOMATOLOGY;

ADULT; AGED; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; TRIAZINES;

EID: 14844286917     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-004-0362-9     Document Type: Article

References (12)

1. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA (1996) A systematic review of antidepressant in neuropathic pain. Pain 68:217-227
2. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes. Drugs 60:1029-1052
3. Archibald CJ, McGrath PJ, Ritvo PG et al (1994) Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 58:89-93
4. Moulin DE, Foley KM, Ebers GC (1988) Pain syndromes in multiple sclerosis. Neurology 38(12):1830-1834
5. Schapiro RT, Baumhefner RW, Tourtellotte WW (1997) Multiple sclerosis: A clinical viewpoint to management. In: Raine CS, McFarland HF, Tourtellotte WW (eds) Multiple sclerosis: Clinical and pathogenetic basis. Chapman&Hall, London, pp 391-420
6. Kanner RM (1999) Treatment of chronic pain. In: Rudick AR, Goodkin DE (eds) Multiple sclerosis therapeutics 38:541-546
7. Ramsaransing G, Zwanikken C, De Keyser J (2000) Drug points: Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 320:1113
8. Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG (1999) Lamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations. Neurology 53(2):433
9. Leandri M, Lunardi G, Inglese M et al (2000) Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 247(7):556-558
10. Solaro C, Lunardi GL, Capello E et al (1998) An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 51(2):609-611
11. Sakurai M, Kanazawa I (1999) Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 15:162-168
12. Meldrum BS (1996) Update on the mechanism of action of antiepileptic drugs. Epilepsia 37[Suppl 6]:S4-S11